Biogen and Eisai remain committed after discontinuation of ENGAGE and EMERGE programmes

22 March 2019 – Pharmaceutical companies Biogen and Eisai have announced the discontinuation of two Phase 3 trials of aducanumab. The decision came after analysis by an independent monitoring committee indicated the trials were unlikely to succeed. Biogen and Eisai will continue to investigate other treatments for Alzheimer’s disease, including anti-amyloid treatment BAN2401. [read more]

Global Perspective Newsletter for February 2019

The February 2019 edition of our Global Perspective Newsletter is now available. Read the latest news from ADI, our partners and member associations, including updates from the WHO Executive Board; the Korean National Institute (KNID)'s symposium; Dementia Alliance International, and much more. [read it now]

El Informe Mundial sobre el Alzheimer 2018 ya está disponible en español

31 de enero de 2019 – El Informe Mundial sobre el Alzheimer 2018 ya está disponible en español en nuestro sitio web. El informe aborda cuestiones claves en la investigación de la demencia, sobre ciencia básica, diagnóstico, descubrimiento de fármacos, reducción de riesgos, epidemiología y cuidados. Descubre lo que tienen que decir los principales investigadores de la demencia a nivel mundial. [Lea más] [read more]

Roche remain committed after discontinuing CREAD programme

30 January 2019 – Pharmaceutical company Roche has announced the discontinuation of their CREAD programme. This was following the finding of two Phase III trials that crenezumab, a possible new drug treatment for Alzheimer’s disease, was not expected to meet its efficacy targets. The Alzheimer’s Prevention Initiative (API) will continue to investigate crenezumab in a pivotal trial to prevent Alzheimer’s disease in healthy people with familial Alzheimer’s disease. Crenezumab was discovered by Swiss biotechnology company AC Immune SA and developed by Roche. [read more]

Syndicate content